Stephens Rates Bio-Techne (TECH) hold, $73 Price Target

Stephens has updated its outlook on Bio-Techne Corporation, setting a new price target of $73.00 alongside a hold rating, a 2.96% upside from the current price.

By EarningsIQ Research Desk · Published Jun 27, 2026, 3:03 AM EDT · Updated Jun 30, 2026, 3:11 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Stephens rated Bio-Techne Corporation ($TECH) "hold" with a $73 price target on June 26, 2026.

Since the rating, $TECH is down 0.1% after 1 week, up 0.9% after 1 month and up 2.3% to date (from the $70.92 close on Jun 26, 2026).

TECH Bio-Techne Corporation

$72.57 +22.19% year to date

Daily close · Oct 16, 2026

Key Points

Stephens analyst Steven Etoch lowered Bio-Techne Corporation NASDAQ: TECH to a hold rating on June 26, 2026, accompanied by a $73.00 price target.
Stephens's $73 price target implies 2.96% upside from Bio-Techne Corporation's ($TECH) current $70.90 share price.
Shares of Bio-Techne recently traded around $70.90, sitting near the upper end of their 52-week range spanning from $43.20 to $72.62.
The broader analyst community tracks an average target of $70.73 across 11 opinions, with the next earnings report expected on November 9, 2026.

Get $TECH trade alerts by text

We text you when insiders, Congress or big funds trade $TECH. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bio-Techne Corporation alert may contain errors. Disclosures

Stephens Updates View on Bio-Techne Stock

Stephens analyst Steven Etoch adjusted his outlook on Bio-Techne Corporation NASDAQ: TECH on June 26, 2026. The firm issued a hold rating on the biotechnology name alongside a price target of $73.00. This change arrives as part of a wider wave of updates from Wall Street firms reviewing their stances on the life science reagents and instruments provider.

Analyst rating track record

Stephens & Co. vs. the S&P 500

YTD return +16.61% hypothetical

All-time return -6.40% S&P 500 +26.06%

vs. S&P 500 -32.46% behind the index

Hypothetical returns from Stephens & Co.'s disclosed trades, not real profit or advice. How we model this.

12-month forecast

$TECH price target

Bio-Techne Corporation daily closes and this analyst's $73 target. Not advice.

Where Bio-Techne Stock Trades Today

Bio-Techne shares recently changed hands at $70.90, putting the equity close to its 52-week peak of $72.62 and well above its low point of $43.20. The current trading price sits just below the new $73.00 target set by Stephens, leaving a slim gap between current market levels and the analyst's expectation. The company trades with a 50-day moving average of $72.12 and a 200-day moving average of $61.51.

Analysts Set New Price Targets

Wall Street firms have recalibrated their positions on the biotechnology company over recent weeks. On August 13, 2026, Wells Fargo downgraded the stock to an Equal-Weight rating with a $73.00 price target. RBC Capital moved its rating to Sector Perform on July 9, 2026, also setting a target of $73.00. TD Cowen joined the group on June 30, 2026, with a hold rating and a $73.00 target, while Benchmark shifted to a hold on the same day without specifying a price target. Citigroup moved the stock to a neutral rating on June 29, 2026, with a $73.00 target, and William Blair adjusted its stance to a market perform rating on June 26, 2026. Baird maintained a neutral stance with a $73.00 target on June 26, 2026. Across 11 tracked opinions, analysts maintain a mean price target of $70.73, with targets ranging from a low of $50.00 up to a high of $73.00.

Inside Bio-Techne Operations

Bio-Techne Corporation develops and manufactures life science reagents, diagnostic products, and automated proteomic analytical tools for research and clinical markets globally. Headquartered in Minneapolis, Minnesota, the company operates through segments focused on protein sciences and diagnostics. These solutions support cell and gene therapy, spatial biology, and molecular diagnostics worldwide.

Looking Ahead for Investors

Market participants will look toward the company's next earnings report, scheduled for November 9, 2026, for fresh updates on revenue and profit metrics. The company carries a forward P/E ratio of 31.42 based on current estimates. Analyst ratings and price targets remain subject to future updates as business conditions evolve.